کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
16818 | 42614 | 2016 | 7 صفحه PDF | دانلود رایگان |

• An antidiabete reagent, 4-HIL was synthesized in recombinant C. glutamicum.
• De novo biosynthesis of 4-HIL was improved in recombinant C. glutamicum.
• Co-expression of ppc with ido was benefit for 4-HIL biosynthesis.
• Co-expression of lysC with ido-ppc was benefit for Asp family amino acids synthesis.
4-hydroxyisoleucine (4-HIL) exhibits unique insulinotropic and insulin-sensitizing activities and is an attractive candidate for the treatment of type II and type I diabetes. In our previous study, l-isoleucine dioxygenase gene (ido) was cloned and overexpressed in an l-isoleucine-producing strain, Corynebacterium glutamicum ssp. lactofermentum SN01, and 4-HIL was produced from the endogenous l-isoleucine (Ile). In this study, ppc and lysC were co-expressed with ido to increase the supply of Ile, the direct precursor of 4-HIL, and to further improve the 4-HIL yield. After 144 h of fermentation, the ido-ppc-expressing strain produced 95.72 ± 1.52 mM 4-HIL, 29% higher than the ido-expressing strain. The co-expression of lysC and ppc with ido resulted in a further 35% increment of carbon flux to l-aspartate family amino acids biosynthesis pathway. However, the conversion ratio of Ile to 4-HIL and the 4-HIL yield decreased to 0.31 mol/mol and 30.16 ± 2.01 mM, respectively, likely due to the decreased IDO activity caused by lower pH and higher intracellular Ile concentration. Therefore, co-expression of ido and ppc was benefit for 4-HIL de novo biosynthesis, while co-expression of lysC with ido and ppc decreased the conversion ratio of Ile to 4-HIL.
Journal: Enzyme and Microbial Technology - Volumes 87–88, June 2016, Pages 79–85